A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
DRUG: INCB053914|DRUG: INCB050465
Number of treatment-emergent adverse events (TEAEs), TEAE is defined as an adverse event reported for the first time or worsening of a pre-existing event after the first dose of study treatment., Up to approximately 6 months
Cmax of INCB053914 in combination with INCB050465, Maximum observed plasma concentration., Day 15|Tmax of INCB053914 in combination with INCB050465, Time to maximum plasma concentration., Day 15|Cmin of INCB053914 in combination with INCB050465, Minimum observed plasma concentration during the dosing interval., Day 15|AUC0-t of INCB053914 in combination with INCB050465, Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration., Day 15|Cl/F of INCB053914 in combination with INCB050465, Oral dose clearance., Day 15|Overall response rate, Defined as the percentage of participants with a complete remission (CR)/complete metabolic response (CMR) or partial remission (PR)/partial metabolic response (PMR) as defined by investigator assessment per revised Lugano classification criteria for lymphomas., Up to approximately 6 months|Duration of response, Defined as the time from first documented evidence of CR/CMR or PR/PMR until disease progression or death from any cause among participants who achieve an objective response, as determined by radiographic disease assessment., Up to approximately 6 months|Progression-free survival, Defined as the time from the date of the first dose of any study drug until the earliest date of disease progression, as determined by radiographic disease assessment, or death from any cause, whichever occurs first., Up to approximately 6 months
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).